In our new study, published in the Journal of Acoustical Society of America, we tested reliability, stability, and sensitivity to change in vowel measurements.
Describing the relationship between disease severity and speech metrics, through listener-based and objective acoustic analysis.
Redenlab has entered into a 5 year collaboration with investigators from North and South America, Australia and Europe to investigate the underlying neural mechanisms of Friedreich ataxia. The study is supported by the Friedreich's Ataxia Research Alliance (FARA) and pharmaceutical industry partners.
We are excited to announce that Redenlab Speech Scientists ranked top 1 AND 2 in the world for dysarthria (most common neuromuscular speech disorder)!
Learn more about the platforms and applications that Redenlab use for software development, documentation, and quality management that is in-line with standards such as FDA 21 CFR Part 22.
Redenlab are proud to be supporting PTC Therapeutics, Inc. Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia.